Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.52
- Piotroski Score 2.00
- Grade N/A
- Symbol (RENB)
- Company Renovaro Biosciences Inc.
- Price $0.50
- Changes Percentage (-0.77%)
- Change -$0
- Day Low $0.49
- Day High $0.54
- Year High $5.25
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.80
- Trailing P/E Ratio -1.61
- Forward P/E Ratio -1.61
- P/E Growth -1.61
- Net Income $-80,650,171
Income Statement
Quarterly
Annual
Latest News of RENB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Berenberg Downgrades PTC to Hold Amid Macro Pressure
Berenberg downgraded PTC to hold due to ongoing macroeconomic challenges in key markets like aerospace and defense. The lowered price target of $196 reflects a 5.8% upside potential. PTC's recent perf...
By Yahoo! Finance | 2 weeks ago -
Buy this tech firm that's quietly automating warehouses with robots, say Berenberg and Citi -- giving it 50% upside
Investment banks recommend buying shares in AutoStore, a Norwegian warehouse automation company, with price targets projecting over 50% gains in 12 months. AutoStore's innovative technology and market...
By CNBC | 3 weeks ago -
ASML Holding N.V. (ASML) Price Targets Adjusted by Analysts; Berenberg and Deutsche Bank Maintain Buy Ratings Amid Advancements in Lithography Technology
Goldman Sachs ranks ASML Holding N.V. (NASDAQ:ASML) 17th among AI superstars. The surge in US tech stocks is driven by AI excitement, not a financial bubble. Tech giants lead, but new AI competitors a...
By Yahoo! Finance | 1 month ago
